An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
No abstract
Main Authors: | Roman-Ulrich Müller, A. Lianne Messchendorp, Henrik Birn, Giovambattista Capasso, Emilie Cornec-Le Gall, Olivier Devuyst, Albertien van Eerde, Patrick Guirchoun, Tess Harris, Ewout J. Hoorn, Nine V.A.M. Knoers, Uwe Korst, Djalila Mekahli, Yannick Le Meur, Tom Nijenhuis, Albert C.M. Ong, John A. Sayer, Franz Schaefer, Aude Servais, Vladimir Tesar, Roser Torra, Stephen B. Walsh and Ron T. Gansevoort |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaslavsky O.Yu.
2022-02-01
|
Series: | Počki |
Online Access: | https://kidneys.zaslavsky.com.ua/index.php/journal/article/view/357 |
Similar Items
-
Is Autosomal Dominant Polycystic Kidney Disease Becoming a Pediatric Disorder?
by: Stéphanie De Rechter, et al.
Published: (2017-12-01) -
Polycystic Kidney Disease Drug Development: A Conference Report
by: Max C. Liebau, et al.
Published: (2023-03-01) -
Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease
by: Djalila Mekahli, et al.
Published: (2023-02-01) -
Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease
by: Keith A. Betts, PhD, et al.
Published: (2024-04-01) -
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
by: Manuel A. Anderegg, et al.
Published: (2020-03-01)